Sorrentino, J. | bioRxiv Science

bioRxiv2025

A small molecule inhibitor of RNA-binding protein IGF2BP3 shows anti-leukemic activity

The RNA-binding protein IGF2BP3 is an oncofetal protein overexpressed in B-acute lymphoblastic leukemia and is critical for leukemogenesis in experimental models. With cancer-specific expression, functional dispensability for normal development, and an unleveraged pro-oncogenic function in mRNA homeostasis, IGF2BP3 represents an excellent target. With no small molecule inhibitors of IGF2BP3 in clinical use, we undertook an effort to identify new IGF2BP3 inhibitors using biochemical methods. A biochemical screen, followed by a cell-based counter screen, led to the identification of compounds with protein-RNA interaction inhibition and leukemic cell growth-inhibitory activity. One of these compounds, designated I3IN-002, shows consistent cell growth-inhibitory activity, altered cell cycle and increased apoptosis in multiple leukemia cell lines, and is the most potent inhibitor of IGF2BP3 reported to date. I3IN-002 was tolerated in mice when administered intraperitoneally and showed potent anti-leukemic activity in a syngeneic transplantation model of MLL-Af4 leukemia. I3IN-002 inhibits the function of IGF2BP3, disrupting in situ binding of IGF2BP3 to target mRNAs, and altering IGF2BP3-dependent gene expression regulation. Furthermore, cell-free and cellular thermal shift assays as well as drug affinity responsive target stability assays support on target activity of I3IN-002 for IGF2BP3. Thus, the identification of I3IN-002 paves the way for the discovery of potent and selective small molecule inhibitors of IGF2BP3.

cancer biology↗

bioRxiv2024

Protein structure, a genetic encoding for glycosylation

Unlike DNA, RNA, and protein biosynthesis, dogma describes glycosylation as primarily determined by intrinsic cellular limitations, such as glycosyltransferase expression and precursor availability. However, this cannot explain the commonly-observed differences between glycans on the same protein. By examining site-specific glycosylation on diverse human proteins, we detected associations between protein structure and glycan structure, broadly generalizable to human-expressed glycoproteins. Through structural analysis of site-specific glycosylation data, we found protein-sequence and structural features consistently correlated with specific glycan features. To quantify these relationships, we present a new amino acid substitution matrix describing "glycoimpact", i.e., the association of primary protein structure and glycosylation. High-glycoimpact amino acids co-evolve with glycosites, and glycoimpact is high when estimates of amino acid conservation and variant pathogenicity diverge. We report thousands of disease variants near glycosites with high-glycoimpact, including several with known links to aberrant glycosylation (e.g., Oculocutaneous Albinism, Jakob-Creutzfeldt disease, Gerstmann-Straussler-Scheinker, and Gauchers Disease). Finally, glycoimpact quantification is validated by studying oligomannose-complex glycan ratios on HIV ENV, differential sialylation on IgG3 Fc, differential glycosylation on SARS-CoV-2 Spike, and fucose-modulated function of a tuberculosis monoclonal antibody. Finally, to test the causality of protein-glycan associations, we created 5 glycoimpact-designed novel Rituximab variants, 4 of which substantially changed glycoprofiles as predicted. In all, we report that site-specific glycan biosynthesis is influenced by underlying protein structure, enabling glycan structure prediction and genetic sequence-guided glycoengineering.

genetics↗